Incontinence Associated DermatitisINCONTECTNCT06978751
Development of a Risk Assessment Tool for Incontinence-associated Dermatitis (IAD): a Cohort Study on the Predictive Performance of Risk Factors for IAD
An observational study of Incontinence Associated Dermatitis, run by Örebro University, Sweden at 7 sites in 2 countries.
Trial summary
Objective: The primary goal of this prospective cohort study is to collect data on specific factors, including age, sex, stool consistency, etc. and assess their association with the development of IAD. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Incontinence Associated Dermatitis
- How many people
- 271 participants
- Where
- 7 sitesin 2 countries
- Study dates
- 13 May 2025to 18 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population includes adult hospitalised patients with urinary, faecal, or double incontinence who are free of IAD at inclusion.
Who may be able to join
- The patient or their legally authorized representative signed informed consent.
- The patient is aged 18 years or older.
- The patient suffers from incontinence* (urinary, faecal, double incontinence).
- The patient is free of IAD at inclusion. *Incontinence is defined as involuntary loss of urine and/or stool.
Who cannot join
- Patients admitted to emergency departments, paediatric units, maternity units, psychiatric units, and palliative care units.
- Patients who are receiving end-of-life care.
Trial locations and contacts
7 sites in 2 countries.
7 sites in 2 countries
Belgium6 sites
AZ Sint-Lucas
Ghent
University Hospital Ghent
Ghent
Sint-Jozefskliniek
Izegem
AZ Groeninge
Kortrijk
AZ Delta
Rumbeke
AZ West
Veurne
About this study
Objective: The primary goal of this prospective cohort study is to collect data on specific factors, including age, sex, stool consistency, etc. and assess their association with the development of IAD. Through the compilation of this data, the study aims to determine whether the identified factors are indeed risk factors for the occurrence of IAD.
Study design: Prospective observational cohort study
Read more
Methodology:
This is a multi-center, prospective cohort study in hospitals in Sweden and Belgium. Adult patients (≥18 years) who are incontinent and free of IAD at baseline will be enrolled following informed consent.
Data collection: Daily skin assessments of the perineal area will be conducted by trained nurses using the validated Ghent Global Incontinence-Associated Dermatitis Tool (GLOBIAD). If IAD is detected, standardized photographs will be taken for blinded central review by skin integrity experts. Clinical, demographic, and care-related data will be collected, including variables such as age, sex, stool consistency, mobility, hygiene practices, nutrition, medication use, and comorbidities.
The primary endpoint for this study is to establish an association between the identified factors and the development of IAD in the study population.
Read the detailed description
Problem Statement:
Incontinence-Associated Dermatitis (IAD) is a type of irritant contact dermatitis caused by prolonged skin exposure to urine and/or feces. It commonly affects individuals with incontinence. IAD is associated with decreased quality of life, increased care burden, loss of independence, and higher susceptibility to secondary infections and pressure ulcers. These complications lead to prolonged hospital stays and increased healthcare costs.
Despite its clinical relevance, there is insufficient consensus regarding the most critical risk factors for IAD. Existing literature points to a wide range of potential contributors including patient demographics, comorbidities, hygiene practices, and care protocols. A comprehensive prospective study is needed to investigate these risk factors within a hospitalized population in order to inform effective prevention and management strategies.
Methodology:
A prospective cohort design will be conducted across multiple hospital settings in Sweden and Belgium. The study targets adult patients, aged 18 years or older, who suffer from urinary, fecal, or double incontinence upon admission to the hospital and are free of IAD at enrollment.
The primary goal of this prospective cohort study is to collect data on specific factors, including age, sex, stool consistency, etc. and assess their association with the development of IAD. Through the compilation of this data, the study aims to determine whether the identified factors are indeed risk factors for the occurrence of IAD.
Data Collection:
Data collection will be managed through an electronic case report form (eCRF) using the RedCap® platform. Nurses will conduct daily inspections of the perianal skin area for each patient, recording observations and, when signs of IAD were identified, capture photographic evidence. These images will be reviewed by a blinded expert panel from the SCENTR team at Örebro University to confirm the diagnosis.
Collected variables include demographic data such as age, sex, and body weight, as well as clinical and care-related factors. These encompass comorbidities (e.g., diabetes, dermatological conditions, Clostridioides difficile infection), cognitive status, smoking habits, nutritional support (including enteral and parenteral nutrition), sedative and vasopressor use, and antibiotic therapy. Care-related variables include the frequency and type of incontinence, the number of absorbent product changes, skin cleansing and barrier product usage, and whether patients are mechanically ventilated. Additionally, functional assessments based on selected Braden Scale subscales-moisture, friction/shear, self-care ability, and mobility-will be recorded. Stool consistency will be classified using the Bristol Stool Chart, with a particular focus on types 6 and 7 (loose and watery stools), which have been previously identified as potential contributors to skin breakdown.
Data Analysis:
Statistical analysis, conducted using SPSS statistical package version 28.0 or later, will involve presenting summary statistics for demographics and clinical characteristics. Univariate analyses will explore associations between potential risk factors and IAD development, employing appropriate tests. Variables with p ≤ 0.2 significance in bivariate analysis will undergo multivariate logistic regression. Beforehand, multicollinearity will be assessed using multiple linear regression, and variables will be removed via the backwards method with P = 0.1 cut-off. Model fit will be evaluated using Nagelkerke R2 and Hosmer-Lemeshow statistic, with significance set at α = 0.05.
- Conditions
- Incontinence Associated Dermatitis
- Keywords
- Dermatitis, Risk factors, Urinary incontinence, Fecal incontinence, Prognosis
- Medical subject headings
- Dermatitis, Urinary Incontinence, Fecal Incontinence
What is being measured
The primary outcome is the main question the study is designed to answer.
Association between prognostic factors and the development of IAD
This outcome will assess the relationship between selected prognostic factors (e.g., age, sex, stool consistency, type of incontinence) and the development of incontinence-associated dermatitis (IAD) in hospitalized incontinent patients. IAD status will be assessed using the GLOBIAD (Ghent Global IAD Categorisation Tool). The association between each prognostic factor and IAD will be evaluated using multivariable logistic regression analysis.
Measured: 12 months
Secondary outcomes (1)
Incidence of Incontinence-Associated Dermatitis (IAD) in hospitalized incontinent patients
The incidence of IAD will be measured as the proportion of hospitalized patients with urinary, fecal, or dual incontinence who develop IAD during their hospital stay. IAD will be assessed using the GLOBIAD (Ghent Global IAD Categorisation Tool).
Measured: 12 months (during the hospital stay of each enrolled patient, over the 12-month study period)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 May 2025
- Study start13 May 2025
- Primary completion18 May 2026
- Study completion18 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Incontinence Associated DermatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 271 participants (actual)
Sponsor and investigators
- Lead sponsor
- Örebro University, Sweden
- Sponsor type
- University, hospital or other
- Collaborators
- University Ghent
- Responsible party
- Sponsor
- Investigators
- Dimitri Beeckman, Professor, PhD, MSc, RN, Principal investigator, Swedish Centre for Skin and Wound Research (SCENTR), School of Health Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06978751
- Sponsor's protocol ID
- ORU 4.2-02319/2021
- Other IDs
- 2021-02653
- Acronym
- INCONTECT
- Status last verified
- May 2026
- First submitted
- 7 May 2025
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Deprez J, Kottner J, Eilegard Wallin A, Ohde N, Baath C, Hommel A, Hultin L, Josefson A, Beeckman D. What are the prognostic factors for the development of incontinence-associated dermatitis (IAD): a protocol for a systematic review and meta-analysis. BMJ Open. 2023 Jul 10;13(7):e073115. doi: 10.1136/bmjopen-2023-073115.
PubMed 37429690Deprez J, Ohde N, Eilegard Wallin A, Baath C, Hommel A, Hultin L, Josefson A, Kottner J, Beeckman D. Prognostic factors for the development of incontinence-associated dermatitis (IAD): A systematic review. Int Wound J. 2024 Jul;21(7):e14962. doi: 10.1111/iwj.14962.
PubMed 39016196
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of a Risk Assessment Tool for Incontinence-associated Dermatitis (IAD): a Cohort Study on the Predictive Performance of Risk Factors for IAD
- ClinicalTrials.gov ID
- NCT06978751
- Acronym / sponsor ID
- INCONTECT / ORU 4.2-02319/2021
- Conditions
- Incontinence Associated Dermatitis
- Keywords
- Dermatitis, Risk factors, Urinary incontinence, Fecal incontinence, Prognosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 271 participants (actual)
- Lead sponsor
- Örebro University, SwedenUniversity, hospital or other
- Collaborators
- University Ghent
- Study start
- 13 May 2025 (actual)
- Primary completion
- 18 May 2026 (actual)
- Study completion
- 18 May 2026 (actual)
- First posted
- 18 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective: The primary goal of this prospective cohort study is to collect data on specific factors, including age, sex, stool consistency, etc. and assess their association with the development of IAD. Through the compilation of this data, the study aims to determine whether the identified factors are indeed risk factors for the occurrence of IAD.
Study design: Prospective observational cohort study
Methodology:
This is a multi-center, prospective cohort study in hospitals in Sweden and Belgium. Adult patients (≥18 years) who are incontinent and free of IAD at baseline will be enrolled following informed consent.
Data collection: Daily skin assessments of the perineal area will be conducted by trained nurses using the validated Ghent Global Incontinence-Associated Dermatitis Tool (GLOBIAD). If IAD is detected, standardized photographs will be taken for blinded central review by skin integrity experts. Clinical, demographic, and care-related data will be collected, including variables such as age, sex, stool consistency, mobility, hygiene practices, nutrition, medication use, and comorbidities.
The primary endpoint for this study is to establish an association between the identified factors and the development of IAD in the study population.
Detailed description
Problem Statement:
Incontinence-Associated Dermatitis (IAD) is a type of irritant contact dermatitis caused by prolonged skin exposure to urine and/or feces. It commonly affects individuals with incontinence. IAD is associated with decreased quality of life, increased care burden, loss of independence, and higher susceptibility to secondary infections and pressure ulcers. These complications lead to prolonged hospital stays and increased healthcare costs.
Despite its clinical relevance, there is insufficient consensus regarding the most critical risk factors for IAD. Existing literature points to a wide range of potential contributors including patient demographics, comorbidities, hygiene practices, and care protocols. A comprehensive prospective study is needed to investigate these risk factors within a hospitalized population in order to inform effective prevention and management strategies.
Methodology:
A prospective cohort design will be conducted across multiple hospital settings in Sweden and Belgium. The study targets adult patients, aged 18 years or older, who suffer from urinary, fecal, or double incontinence upon admission to the hospital and are free of IAD at enrollment.
The primary goal of this prospective cohort study is to collect data on specific factors, including age, sex, stool consistency, etc. and assess their association with the development of IAD. Through the compilation of this data, the study aims to determine whether the identified factors are indeed risk factors for the occurrence of IAD.
Data Collection:
Data collection will be managed through an electronic case report form (eCRF) using the RedCap® platform. Nurses will conduct daily inspections of the perianal skin area for each patient, recording observations and, when signs of IAD were identified, capture photographic evidence. These images will be reviewed by a blinded expert panel from the SCENTR team at Örebro University to confirm the diagnosis.
Collected variables include demographic data such as age, sex, and body weight, as well as clinical and care-related factors. These encompass comorbidities (e.g., diabetes, dermatological conditions, Clostridioides difficile infection), cognitive status, smoking habits, nutritional support (including enteral and parenteral nutrition), sedative and vasopressor use, and antibiotic therapy. Care-related variables include the frequency and type of incontinence, the number of absorbent product changes, skin cleansing and barrier product usage, and whether patients are mechanically ventilated. Additionally, functional assessments based on selected Braden Scale subscales-moisture, friction/shear, self-care ability, and mobility-will be recorded. Stool consistency will be classified using the Bristol Stool Chart, with a particular focus on types 6 and 7 (loose and watery stools), which have been previously identified as potential contributors to skin breakdown.
Data Analysis:
Statistical analysis, conducted using SPSS statistical package version 28.0 or later, will involve presenting summary statistics for demographics and clinical characteristics. Univariate analyses will explore associations between potential risk factors and IAD development, employing appropriate tests. Variables with p ≤ 0.2 significance in bivariate analysis will undergo multivariate logistic regression. Beforehand, multicollinearity will be assessed using multiple linear regression, and variables will be removed via the backwards method with P = 0.1 cut-off. Model fit will be evaluated using Nagelkerke R2 and Hosmer-Lemeshow statistic, with significance set at α = 0.05.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population includes adult hospitalised patients with urinary, faecal, or double incontinence who are free of IAD at inclusion.
Key inclusion criteria (4 listed)
- The patient or their legally authorized representative signed informed consent.
- The patient is aged 18 years or older.
- The patient suffers from incontinence* (urinary, faecal, double incontinence).
- The patient is free of IAD at inclusion. *Incontinence is defined as involuntary loss of urine and/or stool.
Key exclusion criteria (2 listed)
- Patients admitted to emergency departments, paediatric units, maternity units, psychiatric units, and palliative care units.
- Patients who are receiving end-of-life care.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Association between prognostic factors and the development of IAD
Time frame: 12 months
This outcome will assess the relationship between selected prognostic factors (e.g., age, sex, stool consistency, type of incontinence) and the development of incontinence-associated dermatitis (IAD) in hospitalized incontinent patients. IAD status will be assessed using the GLOBIAD (Ghent Global IAD Categorisation Tool). The association between each prognostic factor and IAD will be evaluated using multivariable logistic regression analysis.
1 secondary outcome
Incidence of Incontinence-Associated Dermatitis (IAD) in hospitalized incontinent patients
Time frame: 12 months (during the hospital stay of each enrolled patient, over the 12-month study period)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Background: PubMed 37429690Deprez J, Kottner J, Eilegard Wallin A, Ohde N, Baath C, Hommel A, Hultin L, Josefson A, Beeckman D. What are the prognostic factors for the development of incontinence-associated dermatitis (IAD): a protocol for a systematic review and meta-analysis. BMJ Open. 2023 Jul 10;13(7):e073115. doi: 10.1136/bmjopen-2023-073115.
- Background: PubMed 39016196Deprez J, Ohde N, Eilegard Wallin A, Baath C, Hommel A, Hultin L, Josefson A, Kottner J, Beeckman D. Prognostic factors for the development of incontinence-associated dermatitis (IAD): A systematic review. Int Wound J. 2024 Jul;21(7):e14962. doi: 10.1111/iwj.14962.
- Individual participant dataSharing planned: No
Related trials for Incontinence Associated Dermatitis
Enrolling by invitation
Effect of a Standardized Moisture-Care Protocol Using Skin Barrier Spray on Prevention of Pressure Injuries in the Perineal-Sacral Area Among Incontinent Inpatients: A 3-month Pilot Study.
Pressure Injury, Pressure Injury Prevention
Not yet recruiting
Testing the Safety and Efficacy of a Novel Barrier Cream for the Treatment of Moisture Associated Skin Damage
Moisture Associated Skin Damage, Incontinence Associated Dermatitis
Recruiting
Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent
Fecal Incontinence, Urinary Incontinence
Not yet recruiting
Testing a Novel Barrier Cream for Fecal Incontinence in an Ambulatory Population
Moisture Associated Skin Damage, Fecal Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dimitri Beeckman, Professor, PhD, MSc, RN principal investigator
Swedish Centre for Skin and Wound Research (SCENTR), School of Health Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
7 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Incontinence Associated Dermatitis, run by Örebro University, Sweden at 7 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Belgium, Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Association between prognostic factors and the development of IAD (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06978751, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.